Nationally Recognized Heart Hospital
Dallas   Fort Worth



Find a Physician

Advanced Search


Reduce LAP-HF Trial II

The Corvia Medical InterAtrial Shunt Device (IASD®) System II is indicated for the improvement in quality of life and reduction of heart failure related symptoms and events in patients with heart failure with preserved (HFpEF) or mid-range ejection fraction (HFmrEF) with elevated left atrial pressures, who remain symptomatic despite standard GDMT.

Study objective:
To evaluate the Corvia Medical, Inc. IASD® System II to reduce elevated left atrial pressure in patients with heart failure.

“Currently, there are no common or proven therapies for patients with HFpEF Heart Failure. In this study, we will examine if patients enrolled demonstrate an improvement in functional capacity, quality of life, and reduction of HF symptoms such as shortness of breath and fatigue.” Susan Joseph, MD, principal investigator.

Main/critical inclusion and exclusion criteria: A complete list of inclusion and exclusion criteria for the Reduce LAP-HF Trial II study can be found at: https://clinicaltrials.gov/ct2/show/NCT03088033

Study contact:
Christine Brooks, Christine.Brooks@bswhealth.org, 214.818.2588.

Back to Clinical Trials

Warning

Your Session will expire in 5 minutes

Please click the "Continue Session" button below to continue using the website. To end your session please click the "End Session" button below. After 5 minutes of inactivity your session will be terminated and you will be required to log in again.